Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – Merus gets some competition
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Asco 2021 – Merus’s slight improvement might not win over investors
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.
Asco 2021 – Abstract lift drives first stock moves
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
